Together, these data indicate that among TNBC with high intraepithelial PD-L1 protein, concurrent high antigen presentation function or T-cell activation (or, more likely, both) are required to effect significant reductions in the risk of tumor recurrence. The gene discussed is CD274; the disease is neoplasm.